Figure 3 | Scientific Reports

Figure 3

From: Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression

Figure 3

DPP4i treatment protects against lipoapoptosis in hepatocyte. Graphs showing relative mRNA levels of (a) DPP4 by qPCR (n = 6) and (b) protein level of DPP4 by western blot according to palmitate and DPP4i treatment. Relevant bands from different blots were cropped and grouped together. Original blots are shown in Supplementary Figure S6. Graphs showing relative mRNA levels of ER stress markers (c) ATF4, (d) CHOP (n = 6 per each marker), and (e) TRAIL-R2 (n = 8) by PCR, and (f) protein level of TRAIL-R2 (death receptor 5, DR5) by western blot according to palmitate and DPP4i treatment. Relevant bands from different blots were cropped and grouped together. Original blots are shown in Supplementary Figure S7. Graphs showing (g) caspase 3/7 activity (n = 5), and relative mRNA expression levels of (h) collagen1α1 (n = 5), and (i) αSMA (n = 5) by qPCR according to palmitate and DPP4i treatment. Data in all graphs are presented as mean ± SEM. *p < 0.05; **p < 0.01; NS not statistically significant. Control, HepG2 cells, no treatment; Palmitate, HepG2 cells treated with palmitate (0.6 mM) for 18 h; Palmitate + DPP4i, HepG2 cells treated with teneligliptin (3 μM) for 6 h, followed by palmitate treatment (0.6 mM) for 18 h. Each experiment was repeated as a described number of times in the figure.

Back to article page